Every Form 4 that Erasca, Inc. (ERAS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ERAS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERAS filings page.
Erasca, Inc. reported that President, R&D Charles S. Fuchs received a grant of stock options covering 1,300,000 shares of common stock with an exercise price of $18.12 per share. The award was granted in connection with his commencement of employment and vests 25% after one year, with the remaining 75% vesting in 36 monthly installments, subject to continued service. Following this grant, he holds options for 1,300,000 shares.
Erasca, Inc. director Valerie Denise Harding received a stock option grant covering 29,888 shares of Common Stock. The options have an exercise price of $16.01 per share and expire on June 26, 2036.
All 29,888 options vest on June 26, 2027, provided she remains in continuous service with the company through that date. Following this grant, she holds 29,888 derivative securities directly, reflecting a routine, compensation-related award rather than an open-market purchase or sale.
Erasca, Inc. director Jean I. Liu received a stock option grant covering 29,888 shares of common stock on June 26, 2026. The option has an exercise price of $16.01 per share and expires on June 26, 2036. According to the filing, Liu now holds options for 29,888 shares following this award. The grant vests 100% on June 26, 2027, subject to her continuous service with the company until that date, and represents equity compensation rather than an open-market purchase or sale.
Erasca, Inc. director Pratik S. Multani received a stock option grant covering 29,888 shares of common stock. The option has an exercise price of $16.01 per share and expires on June 26, 2036.
All of these options vest on June 26, 2027, as long as the director continues to serve the company through that date. After this grant, the filing shows 29,888 option shares held directly, with no remaining prior derivative positions listed.
Erasca, Inc. director Alexander W. Casdin received a grant of stock options covering 29,888 shares of common stock. The options have an exercise price of $16.01 per share, expire on June 26, 2036, and vest 100% on June 26, 2027, contingent on his continued service.
Erasca, Inc. director Julie Hambleton reported receiving a stock option grant as part of her compensation. She was awarded options covering 29,888 shares of common stock at an exercise price of $16.01 per share. These options vest 100% on June 26, 2027, provided she continues serving the company through that date, and expire on June 26, 2036. Following this grant, she holds stock options for 29,888 shares directly. This is a compensation-related award rather than an open-market purchase or sale.
Erasca, Inc. director James Arthur Bristol received a grant of stock options as part of his compensation. The award covers 29,888 options to buy common stock at an exercise price of $16.01 per share. These options were granted at no cost on the grant date.
The options vest 100% on June 26, 2027, provided he continues serving the company through that date, and they expire on June 26, 2036. After this grant, he holds 29,888 stock options directly, with no open-market share purchases or sales reported in this filing.
Erasca, Inc. Chief Legal Officer Ebun Garner exercised stock options and sold shares in a planned transaction. On April 1, 2026, Garner exercised options to acquire 80,000 shares of common stock at $1.70 per share, converting a derivative position into common stock.
That same day, Garner sold 80,000 shares of common stock at a weighted-average price of $16.40 per share in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2024. Following these transactions, Garner directly held 25,076 shares of Erasca common stock.
Erasca, Inc. Chief Medical Officer Morris Shannon reported an option exercise and related share sale. On March 4, 2026, he exercised options for 20,000 shares of common stock at $1.70 per share and sold 20,000 shares in open-market transactions at a weighted-average price of $15.038 per share. These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. Following a related derivative entry dated March 4, 2025, he held 515,800 stock options, which vest monthly in 48 installments starting February 1, 2024, contingent on continued service.
Erasca, Inc. Chairman, CEO and 10% owner Jonathan E. Lim reported receiving a stock option grant covering 2,000,000 shares of common stock. The option has an exercise price of $10.31 per share and is held directly.
According to the vesting terms, 1/48 of the option shares vest each month on the 29th (or the last day of February), beginning in February 2026, so long as Lim continues to provide service to Erasca on each vesting date. After this grant, he beneficially owns options for 2,000,000 shares.
Erasca, Inc. reported insider equity activity by its CFO and CBO, David M. Chacko. On 12/15/2025, he acquired 17,793 shares of common stock at $1.1943 per share through the company’s 2021 Employee Stock Purchase Plan, bringing his directly held common shares to 279,980.
On 01/29/2026, he was granted a stock option for 640,000 shares of common stock with an exercise price of $10.31 per share. One forty-eighth of these option shares vest monthly starting in February 2026, conditioned on his continued service to Erasca.
Erasca, Inc. reported a new equity award for its Chief Medical Officer, Morris Shannon. A Form 4 shows a grant of stock options covering 625,000 shares of common stock, with an exercise price of $10.31 per share, dated January 29, 2026.
These options vest over four years: 1/48th of the shares vest each month on the 29th (or the last day of February), beginning in February 2026, as long as Shannon continues serving the company on each vesting date. All 625,000 options are reported as directly owned following this grant.
Erasca, Inc. director Michael David Varney received a stock option award reported as of January 29, 2026. The option covers 96,000 shares of common stock at an exercise price of $10.31 per share and is held directly.
According to the vesting terms, 1/48th of the option vests each month on the 29th day (or the last day of February), beginning in February 2026, so long as Varney continues providing service to Erasca on each vesting date.
Erasca, Inc. reported a stock option grant to its General Counsel and Corporate Secretary, Ebun Garner. The option covers 560,000 shares of Erasca common stock at an exercise price of $10.31 per share and was granted on January 29, 2026.
According to the vesting terms, 1/48th of the shares subject to the option vest monthly on the 29th of each month (or the last day of February), beginning in February 2026, as long as Garner remains in continuous service with the company. After this grant, Garner beneficially owns 560,000 stock options directly.
Erasca, Inc. General Counsel & Corporate Secretary Ebun Garner reported several equity transactions in company stock. On December 15, 2025, Garner acquired 3,902 shares of common stock at $1.1943 per share under Erasca's 2021 Employee Stock Purchase Plan. On January 7, 2026, Garner exercised 120,000 stock options at an exercise price of $1.7 per share and, on the same date, sold 120,000 shares of common stock at a weighted-average price of $5.5901 per share pursuant to a previously adopted Rule 10b5-1 trading plan. Following these transactions, Garner directly held 25,076 shares of common stock and 360,000 stock options that are fully vested and exercisable.